We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Phosphorylated Tau Protein Blood Test Distinguishes Alzheimer’s Disease from Other Neurological Disorders

By LabMedica International staff writers
Posted on 04 May 2020
A recently developed blood test has confirmed the hypothesis that elevated levels of circulating phosphorylated tau 181 (pTau181) protein correlate with Alzheimer's disease (AD) and distinguish it from other neurological disorders that may be misdiagnosed as AD.

Since neurological disorders such as frontotemporal dementia are as common as AD among adults under 65 years of age, simple, widely available screening tests are needed to identify which individuals, with symptoms of cognitive or behavioral decline should be further evaluated for initiation of treatment. More...
A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid-beta positron emission tomography (PET) diagnostic tests.

In an effort to develop a blood-based test for AD, investigators at the University of Gothenburg (Sweden) examined whether plasma tau protein phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and other neurological disorders.

For this purpose, the investigators adapted an assay based on measurement of pTau181 in ordinary blood samples using the extremely sensitive Single Molecule Array (Simoa) technique. The Simoa method can detect considerably lower levels of protein biomarkers than other analytical methods.

The current study included four clinic-based prospective cohorts. The discovery cohort comprised 37 patients with Alzheimer's disease and age-matched controls. Two validation cohorts (226 in TRIAD and 763 in BioFINDER-2) included cognitively unimpaired older adults (mean age 63–69 years), participants with mild cognitive impairment (MCI), Alzheimer's disease, and frontotemporal dementia. In addition, TRIAD included healthy young adults (mean age 23 years) and BioFINDER-2 included patients with other neurodegenerative disorders. The primary care cohort comprised 1131 control participants from the community without a diagnosis of a neurological condition and patients referred from primary care physicians for specialist care.

Results obtained with the Simoa assay revealed that in all cohorts, plasma pTau181 showed gradual increases along the Alzheimer's disease continuum, from the lowest concentrations in amyloid beta-negative young adults and cognitively unimpaired older adults, through higher concentrations in the amyloid beta-positive cognitively unimpaired older adults and MCI groups, to the highest concentrations in the amyloid beta-positive MCI and Alzheimer's disease groups.

Plasma pTau181 distinguished Alzheimer's disease dementia from amyloid beta-negative young adults and cognitively unimpaired older adults, as well as other neurodegenerative disorders (including frontotemporal dementia, vascular dementia, progressive supranuclear palsy, corticobasal syndrome, Parkinson's disease, or multiple systems atrophy). Furthermore, in the primary care cohort, plasma pTau181 discriminated Alzheimer's disease patients from young adults and cognitively unimpaired older adults but not from MCI.

"We believe that, in the future, one very important use of our blood test will be for screening in primary care. We demonstrated this in one of the studies forming part of our article, in which we looked at patients in primary care with concerns about their failing memory," said senior author Dr. Kaj Blennow, professor of clinical neurochemistry at the University of Gothenburg.

The phosphorylated tau 181 assay was described in the May 1, 2020, issue of the journal The Lancet Neurology.

Related Links:
University of Gothenburg


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.